IRD · Categories · Form 4

IRD - SEC Form 4 insider transactions

Opus Genetics Inc. (IRD) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for IRD

• 3d
  SEC Form 4 filed by Rodgers Richard J

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 3d
  SEC Form 4 filed by Manuso James S J

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 3d
  SEC Form 4 filed by Benton Susan

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 3d
  SEC Form 4 filed by Gallagher Cam

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 3d
  SEC Form 4 filed by Graves Adrienne L

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 3d
  SEC Form 4 filed by Bennett Jean

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 3d
  SEC Form 4 filed by Ainsworth Sean

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 38d
  SEC Form 4 filed by Schachle Joseph K

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 38d
  SEC Form 4 filed by Zaremba Rabourn Amy

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 38d
  SEC Form 4 filed by Magrath George

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 38d
  SEC Form 4 filed by Jayagopal Ashwath

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 67d
  Chief Scientific & Dev. Ofc. Jayagopal Ashwath covered exercise/tax liability with 5,313 shares, decreasing direct ownership by 1% to 520,494 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 89d
  President Yerxa Benjamin R was granted 400,000 shares, increasing direct ownership by 125% to 719,005 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 89d
  Chief Operating Officer Schachle Joseph K was granted 250,000 shares, increasing direct ownership by 459% to 304,500 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 89d
  Head of Fin. Quality Assurance Zaremba Rabourn Amy was granted 86,500 shares, increasing direct ownership by 81% to 193,128 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 89d
  Chief Executive Officer Magrath George was granted 483,639 shares, increasing direct ownership by 37% to 1,775,293 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 89d
  Chief Scientific & Dev. Ofc. Jayagopal Ashwath was granted 400,000 shares, increasing direct ownership by 318% to 525,807 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 89d
  Chief Financial Officer Gagnon Robert E. was granted 400,000 shares, increasing direct ownership by 200% to 600,000 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 94d
  Head of Fin. Quality Assurance Zaremba Rabourn Amy covered exercise/tax liability with 3,390 shares, decreasing direct ownership by 3% to 106,628 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 102d
  Head of Fin. Quality Assurance Zaremba Rabourn Amy covered exercise/tax liability with 3,950 shares, decreasing direct ownership by 3% to 110,018 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 107d
  Director Gallagher Cam was granted 67,000 shares, increasing direct ownership by 3% to 1,991,430 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 110d
  Director Manuso James S J was granted 31,188 shares, increasing direct ownership by 12% to 292,951 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 110d
  Director Graves Adrienne L was granted 23,643 shares, increasing direct ownership by 30% to 103,147 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 110d
  Director Bennett Jean was granted 21,127 shares, increasing direct ownership by 10% to 234,652 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 110d
  Director Ainsworth Sean was granted 42,507 shares, increasing direct ownership by 17% to 297,325 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 135d
  Director Foundation Fighting Blindness Retinal Degeneration Fund sold $8,600,000 worth of shares (4,000,000 units at $2.15) (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 171d
  Amendment: Chief Executive Officer Magrath George covered exercise/tax liability with 30,350 shares, decreasing direct ownership by 2% to 1,291,654 units (SEC Form 4)

  4/A - Opus Genetics, Inc. (0001228627) (Issuer)
• 172d
  Chief Executive Officer Magrath George covered exercise/tax liability with 30,350 shares, decreasing direct ownership by 2% to 1,291,654 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 183d
  President Yerxa Benjamin R covered exercise/tax liability with 23,795 shares, decreasing direct ownership by 7% to 319,005 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 226d
  Chief Financial Officer Gagnon Robert E. was granted 200,000 shares (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 241d
  Director Gallagher Cam was granted 869,565 shares, increasing direct ownership by 92% to 1,810,430 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 241d
  Director Ainsworth Sean was granted 86,956 shares, increasing direct ownership by 52% to 254,818 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 354d
  Director Foundation Fighting Blindness Retinal Degeneration Fund converted options into 6,927,419 shares (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 358d
  Director Rodgers Richard J was granted 79,504 shares, increasing direct ownership by 33% to 318,655 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 358d
  Director Manuso James S J was granted 79,504 shares, increasing direct ownership by 44% to 261,763 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 358d
  Director Graves Adrienne L was granted 79,504 shares (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 358d
  Director Gallagher Cam was granted 79,504 shares, increasing direct ownership by 9% to 940,865 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 358d
  Director Benton Susan was granted 79,504 shares, increasing direct ownership by 57% to 219,527 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 358d
  Director Bennett Jean was granted 79,504 shares, increasing direct ownership by 59% to 213,525 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 358d
  Director Ainsworth Sean was granted 79,504 shares, increasing direct ownership by 90% to 167,862 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 395d
  Chief Executive Officer Magrath George was granted 392,157 shares, increasing direct ownership by 42% to 1,322,004 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 395d
  Director Gallagher Cam was granted 784,314 shares, increasing direct ownership by 1,018% to 861,361 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 404d
  Chief Operating Officer Schachle Joseph K was granted 52,500 shares, increasing direct ownership by 2,625% to 54,500 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 404d
  SVP of Finance Zaremba Rabourn Amy was granted 39,500 shares, increasing direct ownership by 53% to 113,968 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 404d
  Chief Executive Officer Magrath George was granted 330,697 shares, increasing direct ownership by 55% to 929,847 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 404d
  Chief Financial Officer Jhaveri Nirav S. was granted 52,500 shares, increasing direct ownership by 37% to 194,293 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 404d
  Chief Scientific & Dev. Ofc. Jayagopal Ashwath was granted 52,500 shares, increasing direct ownership by 72% to 125,807 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 404d
  SVP of Corp. Dev. Hoffmann Bernhard was granted 29,500 shares, increasing direct ownership by 19% to 185,446 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 431d
  Chief Financial Officer Jhaveri Nirav S. covered exercise/tax liability with 8,207 shares, decreasing direct ownership by 5% to 141,793 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 431d
  Chief Scientific & Dev. Ofc. Jayagopal Ashwath covered exercise/tax liability with 5,193 shares, decreasing direct ownership by 7% to 73,307 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 443d
  SVP of Finance Zaremba Rabourn Amy covered exercise/tax liability with 8,190 shares, decreasing direct ownership by 10% to 74,468 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 443d
  SVP of Corp. Dev. Hoffmann Bernhard covered exercise/tax liability with 6,751 shares, decreasing direct ownership by 4% to 155,946 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 474d
  Director Manuso James S J was granted 50,222 shares, increasing direct ownership by 38% to 182,259 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 474d
  Director Bennett Jean was granted 34,021 shares, increasing direct ownership by 34% to 134,021 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 488d
  Chief Executive Officer Magrath George was granted 6,200 shares, increasing direct ownership by 1% to 499,150 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 529d
  President Yerxa Benjamin R was granted 332,800 shares (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)
• 536d
  Chief Executive Officer Magrath George covered exercise/tax liability with 37,050 shares, decreasing direct ownership by 9% to 392,950 units (SEC Form 4)

  4 - Opus Genetics, Inc. (0001228627) (Issuer)

Other IRD categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends